Mevac Lasota +H120

Indications

• Measles
• Mumps
• Rubella
• Yellow fever
• Varicella (chickenpox)
• Rotavirus

Dosage

Children: Refer to specific vaccine guidelines for paediatric dosing.

Adults: Refer to specific vaccine guidelines for adult dosing.

Mechanism of action

Attenuated vaccines work by mimicking a natural infection. The weakened pathogen replicates in the body, stimulating the immune system to produce a response against it, which includes the activation of T-cells and the production of antibodies. This prepares the immune system to recognize and fight off the pathogen if exposed in the future.

Pharmacodynamics

The pharmacodynamics of attenuated vaccines involve the interaction of the attenuated pathogen with the host's immune system. Upon administration, the vaccine induces both humoral (antibody-mediated) and cell-mediated immunity. This leads to the development of memory cells that ensure a faster and more effective response upon subsequent exposure to the actual pathogen.

Pharmacokinetics

Attenuated vaccines are generally administered via subcutaneous or intramuscular injection. The pharmacokinetics are characterized by the distribution of the vaccine components within the body, with the attenuated organisms replicating locally and inducing an immune response. The onset of immunity typically occurs within weeks, and the duration of immunity can vary depending on the specific vaccine.

Contra-indications

• Severe immunodeficiency
• Pregnant women (specific live attenuated vaccines)
• Severe allergic reactions to vaccine components

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Low-grade fever
• Malaise
• Rash
• Rare neurological complications (e.g., Guillain-Barré syndrome)

Interactions

• Immunosuppressive agents (may reduce vaccine efficacy)
• Blood products (may interfere with immune response to vaccine)
• Other live vaccines (timing may affect immune response)

Precautions

• History of allergic reactions to previous vaccinations
• Presence of active infections
• Chronic illnesses that may affect immune response

Pregnancy

Live attenuated vaccines are generally contraindicated during pregnancy due to potential risks to the fetus.

Breast-feeding

Most live attenuated vaccines are considered safe during breastfeeding, but caution and consultation with a healthcare provider are advised.

Storage

Store in a refrigerator at 2-8°C. Do not freeze. Protect from light.

Formulations

• Injectable suspension
• Oral suspension
• Lyophilized powder for reconstitution

Indications

• Acute bronchitis
• Chronic bronchitis
• Bronchiectasis
• Chronic obstructive pulmonary disease (COPD)

Dosage

Children: Refer to BNF for Children for appropriate dosing based on the child's age, weight, and the severity of the condition.

Adults: Refer to specific treatment guidelines or BNF for dosing recommendations based on the severity of the condition and the type of medication used.

Mechanism of action

In bronchitis, the inflammation leads to hypersecretion of mucus and bronchoconstriction. Treatment often includes bronchodilators to relax airway muscles and anti-inflammatory agents to reduce swelling. In cases of bacterial bronchitis, antibiotics may be used to target the offending pathogens.

Pharmacodynamics

The pharmacodynamics of drugs used in bronchitis focus on reducing inflammation and bronchoconstriction, facilitating easier breathing. Bronchodilators work by stimulating beta-adrenergic receptors to induce bronchodilation, while corticosteroids reduce inflammatory responses in the airways.

Pharmacokinetics

The pharmacokinetics of drugs prescribed for bronchitis vary. For example, bronchodilators are rapidly absorbed and act within minutes, while corticosteroids may take longer to exert their full effects. The distribution of these drugs occurs systemically, with metabolism primarily in the liver and excretion through urine.

Pregnancy

Consult a healthcare professional before use, as safety during pregnancy has not been fully established.

Breast-feeding

Consult a healthcare professional before use, as it is unclear if the drug passes into breast milk.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Control of broadleaf weeds
• Control of grasses in crops

Mechanism of action

Chlorimuron ethyl inhibits acetolactate synthase (ALS), an enzyme critical for the synthesis of branched-chain amino acids valine and isoleucine. This inhibition disrupts the production of these essential amino acids, halting cell division and leading to the cessation of plant growth. The selectivity for certain crops is due to differential metabolism in plants, involving processes such as homoglutathione conjugation and de-esterification.

Pharmacodynamics

As a herbicide, chlorimuron ethyl exhibits selective toxicity towards certain weed species while sparing desirable crops. The effectiveness of chlorimuron ethyl is reliant on its ability to penetrate plant tissues and reach the target enzyme, ALS, leading to the inhibition of amino acid synthesis and subsequent plant death.

Pharmacokinetics

Chlorimuron ethyl is absorbed by plant roots and foliage, with translocation occurring within the plant system. The herbicide is metabolized through various pathways that contribute to its selectivity and efficacy. The exact pharmacokinetic parameters in humans are not typically studied, as chlorimuron ethyl is primarily utilized in agricultural applications.

Pregnancy

Use in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Use with caution. The effects on a nursing infant are unknown.

Storage

Store in a cool, dry place away from direct sunlight.

Formulations

• {'name': 'Chlorimuron-ethyl', 'type': 'Herbicide', 'strength': 'Various formulations available'}

Dosage

Children: Refer to specific medications used to treat the particular disease for dosing information.

Adults: Refer to specific medications used to treat the particular disease for dosing information.

Mechanism of action

The mechanism of action varies significantly depending on the specific disease in question. For infectious diseases, pathogens may interact with host cells, leading to inflammation, immune response activation, or tissue damage. Chronic diseases often involve complex interactions between genetic factors, lifestyle choices, and environmental influences. For example, in autoimmune diseases, the immune system mistakenly targets healthy cells, leading to inflammation and tissue destruction.

Pharmacodynamics

Pharmacodynamics of disease involves understanding how the disease state affects physiological functions and the body's response to treatment. In infectious diseases, the presence of pathogens can lead to altered immune responses, while chronic diseases may involve changes in metabolic pathways, hormonal balances, or cellular functions. Medications targeting disease processes aim to restore normal function, alleviate symptoms, or eradicate pathogens.

Pharmacokinetics

Pharmacokinetics is not applicable to the term 'disease' as it refers to the movement of drugs within the body, including absorption, distribution, metabolism, and excretion of specific medications used to treat diseases. Each medication will have its own pharmacokinetic profile depending on its chemical properties and the disease being treated.

Indications

• Bacterial infections
• Viral infections
• Fungal infections
• Parasitic infections
• Sepsis
• Pneumonia
• Urinary tract infections
• Skin and soft tissue infections

Dosage

Children: Refer to specific drug monographs for dosing information based on the type of infection and child's age and weight.

Adults: Refer to specific drug monographs for dosing information based on the type of infection and pathogen involved.

Mechanism of action

The mechanism of action of antimicrobial agents varies widely depending on the class of drug. For example, antibiotics may inhibit cell wall synthesis, protein synthesis, or nucleic acid synthesis in bacteria. Antivirals often target viral replication processes, while antifungal agents disrupt cell membrane integrity or inhibit essential metabolic pathways in fungi.

Pharmacodynamics

Pharmacodynamics of infectious disease treatments involves understanding the drug's effects on the pathogen, including the minimum inhibitory concentration (MIC) that inhibits bacterial growth, or the time and concentration needed to effectively reduce viral load. The efficacy of the antimicrobial therapy is influenced by factors such as the site of infection, the immune response of the host, and the susceptibility profile of the pathogen.

Pharmacokinetics

Pharmacokinetics of antimicrobial agents encompasses absorption, distribution, metabolism, and excretion. For instance, antibiotics may be well absorbed orally but have variable bioavailability. Distribution can be affected by tissue permeability and protein binding. Metabolism may occur in the liver, and excretion is primarily renal, influencing dosing in patients with renal impairment.

Pregnancy

Consult healthcare professional; safety varies by specific infectious agent and treatment.

Breast-feeding

Consult healthcare professional; safety varies by specific infectious agent and treatment.

Storage

Store in a cool, dry place, away from direct sunlight; specific storage may vary by formulation.

Indications

• Acute lymphoblastic leukemia (ALL)
• Acute myeloid leukemia (AML)
• Lymphoblastic lymphoma

Dosage

Children: Refer to specific guidelines as dosing may vary based on protocol and patient response.

Adults: Refer to specific guidelines as dosing may vary based on protocol and patient response.

Mechanism of action

Lasota functions as a recombinant enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. This enzymatic reaction reduces the availability of asparagine in the bloodstream, which is crucial for the survival of lymphoid cells. Tumors, particularly lymphoblastic leukemia cells, are unable to synthesize asparagine due to the lack of asparagine synthetase, making them susceptible to this depletion.

Pharmacodynamics

The pharmacodynamic effects of lasota are centered on its ability to induce asparagine depletion, leading to apoptosis in asparagine-dependent neoplastic cells. The effectiveness of lasota is influenced by the concentration of asparagine in the body and the sensitivity of the tumor to asparagine depletion. The therapeutic window is critical, as excessive depletion can lead to adverse effects.

Pharmacokinetics

Lasota has a unique pharmacokinetic profile characterized by a short half-life and variable distribution in the body. It is administered intravenously and is rapidly distributed to tissues. The elimination of lasota primarily occurs through hydrolysis and is influenced by the patient's body weight and the presence of enzymes in the blood. Due to its enzyme nature, it does not have a traditional clearance mechanism related to liver or kidney function, making dosing adjustments less straightforward.

Pregnancy

There is limited data on the use of lasota during pregnancy. Caution is advised, and it should only be used if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether lasota is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Indications

• Measles
• Mumps
• Rubella
• Varicella (chickenpox)
• Yellow fever
• Rotavirus
• Intranasal influenza

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and vaccine type.

Adults: Refer to specific product guidelines for dosing information, as it can vary by vaccine type and brand.

Mechanism of action

Live vaccines work by introducing a weakened or attenuated form of a pathogen into the body. This stimulates the immune system to recognize and respond to the pathogen, leading to the production of antibodies and memory cells that provide long-term protection against future infections by the same pathogen.

Pharmacodynamics

The pharmacodynamics of live vaccines involve the activation of both humoral and cellular immunity. Following vaccination, the immune system generates a robust response, including the production of specific antibodies and the activation of T cells that can recognize and eliminate infected cells. This dual action helps establish long-term immunity.

Pharmacokinetics

The pharmacokinetics of live vaccines vary depending on the specific vaccine. Generally, the vaccine is administered via injection, allowing the live attenuated organisms to enter the bloodstream. The immune response typically begins within days and can last for years, depending on the vaccine. Live vaccines are usually stored under refrigeration to maintain their viability, and they should be administered within their expiration dates.

Interactions

• livevaccines + abrocitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + baricitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + filgotinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + dexrazoxane: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + iron chelators: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ponesimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + upadacitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + diroximelfumarate: Moderate (increases risk of generalised infection (possibly life-threatening))

Indications

• Prevention of Newcastle disease in poultry
• Potential oncolytic therapy in cancer treatment

Dosage

Children: Refer to specific treatment protocols or clinical guidelines for dosages, as they may vary based on the context of use.

Adults: Refer to specific treatment protocols or clinical guidelines for dosages, as they may vary based on the context of use.

Mechanism of action

Newcastle disease virus exerts its effects primarily through the induction of apoptosis in infected cells and the activation of the host immune system. The virus binds to specific receptors on the surface of host cells, facilitating viral entry and replication. It leads to the release of pro-inflammatory cytokines and enhances the anti-tumor immune response in the context of oncolytic therapies.

Pharmacodynamics

The pharmacodynamics of Newcastle disease virus involves its ability to replicate in tumor cells, leading to cell lysis and release of viral progeny that can further infect and destroy adjacent tumor cells. The host's immune system is subsequently activated, enhancing the overall anti-tumor response.

Pharmacokinetics

The pharmacokinetics of Newcastle disease virus is complex, as it involves viral replication and dissemination within the host. Following administration, the virus replicates at the site of infection, with peak viral loads observed at various time points depending on the route of administration and the host's immune status. The virus is typically cleared by the immune system over time, although its persistence can vary based on the type of host cells infected.

Pregnancy

Safety in pregnancy has not been established. Use with caution and only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Safety during breastfeeding is not well established. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight and heat. Follow specific storage requirements if available.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

Mechanism of action

Sulfonylurea class herbicide that inhibits acetolactate synthase, which regulates plant growth. Branched chain amino acid synthesis (ASL or AHAS) inhibitor. Acts by inhibiting biosynthesis of the essential amino acids valine and isoleucine, hence stopping cell division and plant growth. Crop selectivity derives from plant metabolism both by homoglutathione conjugation and by de-esterification. ...Acetolactate synthase /is/ the target enzyme of chlorimuron ethyl.